2025 third_quarter Filing

Tracking Bills S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients.